|
||||||||||||||||||||||
|
|
| Upcoming Programs | ||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
Overview
Rheumatoid arthritis (RA) is a complex immunologic and chronic inflammatory disease that affects more than 2 million people in the United States. Characterized by inflammation of the joints, periarticular bone resorption and cartilage destruction, RA is also an inherently aggressive, systemic disease that leaves patients vulnerable to comorbidities such as cardiovascular disease, osteoporosis, lymphoma, infection, and stroke. While primary care clinicians may not directly treat the disease long term, they are the first to come in contact with potential RA patients. Therefore it is important for all clinicians to be aware of the necessary steps in RA diagnostic and treatment modalities.
Objectives
Identify 3 early warning signs of rheumatoid arthritis (RA)
Describe current and evolving treatment options for RA, and be alert to monitoring and side effects related to these therapies
Faculty
John R.P. Tesser, MD, FACP, FACR
Rheumatologist
Arizona Arthritis and Rheumatology Associates, P.C.
Paradise Valley, AZ
Overview
More than 20 million people in the United States are affected by diabetes, with 1.5 million new cases appearing each year. Of this population, nearly 65% will die from heart disease or stroke, a rate that is 4-times higher than in the non-diabetic population. Individualized and early glycemic control is critical in the prevention and management of diabetes and in reducing cardiovascular risk. This activity will expose attendees to the relationship between insulin resistance, type 2 diabetes, and the resulting cardiovascular risk in an effort to uncover effective treatment strategies and patient-based therapeutic options.
Objectives
Utilize appropriate glucose-lowering agents to reduce A1C to * 7.0%
Minimize adverse events and cardiovascular risk associated with glycemic therapy by employing appropriate glucose, blood pressure, and serum cholesterol agents
Faculty
Stephen Clement, MD
Associate Professor of Medicine
Division of Endocrinology
Georgetown University Medical Center
Acting Chief, Division of Endocrinology
Georgetown University Hospital
Washington, DC
Natasa Janicic-Kahric, MD, PhD
Assistant Professor of Medicine
Division of Endocrinology and Metabolism
Georgetown University Hospital
Washington, DC
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
Benjamin J. Ansell, MD
Assistant Professor of Internal Medicine
University of California, Los Angeles (UCLA) School of Medicine
Los Angeles, CA
Daniel E. Diamond, MD, FAAFP
Assistant Clinical Professor, Department of Family Medicine
University of Washington School of Medicine
Seattle, WA
Overview
Despite a high prevalence in the United States, insomnia remains underdiagnosed and undertreated. Extensive research has identified several factors that contribute to the inadequate treatment of insomnia, including the failure of patients to report insomnia to clinicians and clinician misperceptions about the risks associated with hypnotic medications. This program will address effective strategies for diagnosing and treating patients with insomnia.
Objectives
Identify risk factors, determine appropriate screening tools, and accurately diagnose insomnia
Evaluate current and emerging nonpharmacologic and pharmacologic therapies for acute and chronic insomnia on the basis of efficacy and safety and apply this knowledge/skill with patients
Faculty
Joseph A. Lieberman III, MD, MPH
Professor of Family Medicine
Jefferson Medical College
Thomas Jefferson University
Associate Editor, Delaware Medical Journal
Philadelphia, PA
Thomas C. Neylan, MD
University of California, San Francisco
San Francisco, CA
Overview
ÒMore Than Skin Deep: Clinical Strategies for Acne Vulgaris and Actinic KeratosisÓ is a continuing medical education program that aims to bridge some of the existing professional practice gaps that primary care clinicians may have regarding common dermatologic problems. This program will educate clinicians in the primary care setting about the prevalence, impact, diagnosis, and treatment of both acne vulgaris and actinic keratosis.
Objectives
Confidently diagnose patients presenting with the basic dermatologic conditions of acne vulgaris and actinic keratosis
Identify the most commonly used treatments for acne vulgaris and actinic keratosis
Faculty
Seth Orlow, MD, PhD
Chair, Department of Dermatology
Samuel Weinberg Professor of Pediatric Dermatology
Professor of Cell Biology and Pediatrics
New York University School of Medicine
New York, NY
Andrea L. Zaenglein, MD
Dermatologist
Department of Dermatology Milton S. Hershey Medical Center Pennsylvania State University
Hershey, PA
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Anthony Montanaro, MD
Oregon Health and Science University
Portland, Oregon
Eli Meltzer, MD
Clinical Professor of Pediatrics
University of California, San Diego, School of Medicine
Co-Director
Allergy and Asthma Medical Group and Research Center
San Diego, California
Overview
Bipolar disorder (BD) and major depressive disorder (MDD) are two of the most prevalent psychiatric disorders in adults. These conditions are associated with overlapping disorders of mood including anxiety and depression; differentiating the two disorders can be difficult and can lead to misdiagnosis and mismanagement. This activity will focus on practical approaches to the diagnosis and management of the Òdifficult-to-treatÓ patient presenting with depression associated with MDD and BD.
Objectives
Recognize overlapping symptomatology and comorbid psychiatric disorders that can complicate the differential diagnosis of depression
Design and implement practical strategies to diagnosis and manage the difficult-to-treat patient with depression associated with major depressive disorder and bipolar disorder
Faculty
Larry Culpepper, MD, MPH
Professor of Family Medicine
Department of Family Medicine Chair
Boston University School of Medicine
Chief of Family Practice
Boston Medical Center
Boston, MA